Blog - Page 3673 of 5645

WednesdaySep 08, 2010 7:41 am

Oragenics, Inc. (ORNI.OB) Announces Availability of EvoraPlus® Oral Care Probiotics in Nationwide GNC Stores

Oragenics, Inc., a Florida-based biopharmaceutical company focused primarily on oral health products and novel antibiotics, recently announced that its oral care probiotic EvoraPlus® is expected to be available at corporate-owned GNC stores nationwide. Additionally, Oragenics’ oral care probiotic for children, EvoraKids™, will be available in GNC concept stores and on GNC.com. The company’s oral care probiotic’s active ingredient is ProBiora3®, which naturally supports gum and tooth health while freshening breath and whitening teeth. Developed by Oragenics’ chief scientific officer, Dr. Jeffrey Hillman, D.M.D., Ph.D., this technology has only recently become available to the general public. ProBiora3 is 100 percent natural…

TuesdaySep 07, 2010 3:46 pm

Bond Laboratories’ (BNLB.OB) Resurrection Anti-Hangover Drink a Hit During the Attica 2 Year Anniversary Party

Bond Laboratories, Inc. issued a press release to detail the success of its “Resurrection Anti-Hangover” drink (“REZ”) as it was a sponsor at the Attica 2 Year Anniversary White Party held at Plunge, the new 3 level rooftop lounge at the Gansevoort Park Avenue Hotel in New York City, NY on August 26th. Plunge Rooftop Bar & Lounge is a rooftop wonderland that is located twenty stories above Manhattan with 360 degree views of NYC including a picturesque view of the Empire State Building. Attica, the exclusive, members-only club, was one of the first to host a party at Plunge…

TuesdaySep 07, 2010 2:29 pm

GelTech Solutions Inc. (GLTC.OB) Signs $5M Purchase Agreement with Lincoln Park Capital Fund

GelTech, www.GelTechSolutions.com – a company that helps save water while revolutionizing firefighting with products like the patent pending FireIce® fire suppressant, announced today that it has signed a purchase agreement for up to $5M with institutional investor Lincoln Park Capital Fund LLC. Lincoln has long served as a Chicago institution, managing a broad portfolio of private/public investments covering everything from life sciences to energy and technology. CEO of GLTC, Michael Cordani, commented on the funding agreement with the forward-thinking Lincoln, noting the Company’s lack of any obligation to use the facility, and its intention to apply proceeds from the agreement…

TuesdaySep 07, 2010 2:26 pm

CentraCan, Inc. (CTCJ.OB) Subsidiary Partners with Choice Hotels to Offer Green Battery Solution

CentraCan, a holding company with subsidiaries/JVs focused on sustainable solutions and eco-conscious products like the recyclable alkaline batteries offered through PerfPower Corporation, announced today that PerfPower™ Go-Green™ alkaline batteries with free recycling would be prominently featured and offered by Choice Hotels franchised properties, including Comfort Inn, Comfort Suites and Clarion, to name but a few. As a leader among eco-minded hotels, Choice Hotels International, Inc. – which franchises over 6k hotels in 35 countries, with another 580 or so under construction – is making this move toward a sustainable future by offering eco-conscious travelers a way to help reduce carbon…

TuesdaySep 07, 2010 1:09 pm

Helix Wind Corp. (HELX.OB) Receives Purchase Order for S594 Wind Turbines

Helix Wind Corp. is a global renewal energy company engaged in the design, manufacture and sales of small wind vertical axis turbines designed to generate 300 watts, 1 kilowatt, 2 kilowatts or 4.5 kilowatts of clean, renewable electricity. The company announced today that in cooperation with its distributor, SWG Energy, it has accepted a purchase order to provide twenty-four of its low-noise S594 wind turbines for the Oklahoma Medical Research Foundation (OMRF). This additional purchase order was received after installation and successful completion of standard testing for two units that were previously sold to the facility as part of the…

TuesdaySep 07, 2010 1:07 pm

NeoStem (NBS) Appoints Seasoned President and Managing Director

NeoStem Inc. develops stem cell-based therapies and has built a network of adult stem cell collection centers in the U.S. and China. The company today announced Ian Zhang, Ph.D., MBA, as its new president and managing director. Dr. Zhang holds an MBA from the University of Chicago, Graduate School of Business and holds a Ph.D. in biotechnology from Simon Fraser University. He continued his education as a postdoctoral fellow at Yale University School of Medicine. Dr. Zhang is focused on growth strategy and acquisitions/integrations in the biotech field, with a primary dedication to biotech growth in Asia. He has extensive…

TuesdaySep 07, 2010 12:21 pm

Micro Identification Technologies, Inc. (MMTC.OB) Offers Best Solution to Major Problem

If ever there was a company that has lived up to the old business adage “Find a good solution to an important problem”, it is California based Micro Identification Technologies Inc. There’s little question about the importance of the issue they are addressing, the growing need for quicker and easier identification of potentially deadly bacteria. The increasing globalization and industrialization of the world’s food supply has made the potential for contamination a threat that can affect food consumers everywhere. • Microbial contamination, in hospitals and food products, has grown in recent years. • Accurate identification of contamination typically takes at…

TuesdaySep 07, 2010 11:30 am

China Direct Industries, Inc. (CDII) Video Chart for Tuesday, September 7, 2010

CDII is forming a base at $.94 and appears to be trying to make a move north. While the indicators have given a “head-fake” in the past, they are aligned again for a possible move. Please click the following link: http://www.qualitystocks.net/videocharts.php Let us hear your thoughts below:

TuesdaySep 07, 2010 10:21 am

Rexahn Pharmaceuticals (RNN) Submits Phase IIb Protocol to FDA for Major Depressive Disorder Treatment

Rexahn Pharmaceuticals Inc., a clinical stage company focused on developing and commercializing oncology and CNS therapeutics, has submitted a phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin to assess the drug’s efficacy as treatment for major depressive disorder (MDD). The double blind, randomized, placebo-controlled trial will involve approximately 300 subjects, and will be conducted at multiple sites in the U.S. The study will measure the change from the baseline, with the Montgomery-Asberg Depression Rating Scale (MADRS) as the primary efficacy endpoint. In Rexahn's phase IIa proof of concept study, Serdaxin demonstrated…

TuesdaySep 07, 2010 10:20 am

Elecsys Corp. (ESYS) Reports Second Fiscal Quarter Results

Elecsys Corporation reported a large increase in revenue on a year over year basis in the second quarter of fiscal 2010, which ended 7/31/2010. The company attributed the increase to strong demand for both its existing and newly introduced products. Elecsys Corporation reported revenue of $5.2 million in the second quarter of fiscal 2010, compared to revenue of $3.6 million in the second quarter of fiscal 2009. Elecsys Corporation also improved its net income in the most recent quarter compared to the same quarter in fiscal 2009. Elecsys Corporation reported net income of $0.01 million, or $0.03 per diluted share,…

Site Search

Company Search